Generation Bio

Generation Bio FCF Growth

Delisted

The Year-over-Year Free Cash Flow Growth of Generation Bio (GBIO) as of Nov 10, 2026 is -51.25 %. In the previous year, Year-over-Year Free Cash Flow Growth was 45.94 % — a change of -211.56% (lower).

FCF Growth

-51.25 %

YoY

-211.56%

Last updated:

Year-over-Year Free Cash Flow Growth of Generation Bio is 2024 -51.25 % . Year-over-Year Free Cash Flow Growth of Generation Bio was 2023 45.94 % . It decreases by -211.56% lower compared to the previous year.

The Generation Bio FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2019
-93.74 USD
Jan 1, 2020
-25.41 USD
Jan 1, 2021
-29.23 USD
Jan 1, 2022
-13.78 USD
Jan 1, 2023
45.94 USD
Jan 1, 2024
-51.25 USD
The Generation Bio FCF Growth history
YEARFCF GrowthYoY
-51.25 %-211.56%
45.94 %-433.47%
-13.78 %-52.88%
-29.23 %+15.07%
-25.41 %-72.90%
-93.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Generation Bio Stock analysis

What does Generation Bio do? Generation Bio Co. is a genetic medicines company headquartered in Cambridge, Massachusetts, that focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The firm is developing a class of gene therapy utilizing its non-viral gene therapy platform to deliver genetic payloads to a range of tissues. The company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The firm is engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The firm is a preclinical stage company and have not identified a product candidate. Generation Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Generation Bio stock

Year-over-Year Free Cash Flow Growth of Generation Bio is -51.25 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Generation Bio since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Generation Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Generation Bio

All Key Metrics — Generation Bio